Raynauds finger management
Reading File
Finding Sources
Finding Sources
Searching PubMed
Raynaud phenomenon AND treatment
Searching the Web
Raynaud's phenomenon management NHS keep warm when emergency medical care
Raynaud’s fingers are usually managed by preventing cold-triggered blood-vessel spasm and checking whether there is an underlying cause.
During an attack
- Move to a warm place and gently warm the hands under warm, not hot, water or against warm skin.
- Wiggle fingers and relax slow breathing if stress is a trigger.
- Do not use very hot water, heating pads, or direct flames if the fingers are numb, as burns can occur.
Prevention
- Keep your whole body warm, not only your hands: layers, warm socks, hat, insulated gloves or mittens. Put gloves on before going outside or handling cold items.
- Avoid abrupt temperature changes. Consider hand warmers or heated gloves for frequent episodes.
- Stop smoking or vaping nicotine. Limit caffeine if it triggers attacks.
- Regular exercise and stress-management techniques may reduce episodes.
- Review potential triggers with a clinician, including vibrating tools and medicines that can worsen Raynaud’s, such as some beta-blockers, decongestants, migraine vasoconstrictors, and stimulant medications. The NHS self-care advice supports these measures.
Medicines
If attacks remain frequent, painful, or disruptive despite these steps, a clinician may prescribe a blood-vessel relaxant. Long-acting calcium-channel blockers, typically nifedipine or amlodipine, are usual first choices. They can cause dizziness, flushing, ankle swelling, or low blood pressure, so they should be selected and monitored by a prescriber. Medical textbook guidance similarly describes nifedipine or amlodipine as common first-line drug options.
More advanced treatments are reserved for severe secondary Raynaud’s, especially with systemic sclerosis or digital ulcers, and should be handled by rheumatology or vascular specialists.
Get medical assessment soon if
- Symptoms first began after age 30, are severe, or affect only one hand/few fingers.
- You have sores, pits, ulcers, infection, persistent numbness, or worsening pain.
- You also have joint pain/swelling, skin tightening, rashes, muscle weakness, reflux or swallowing difficulty, or shortness of breath. These can suggest a connective-tissue disease.
Seek urgent care today
If a finger stays white/blue/black and painful after warming, becomes cold with persistent loss of sensation, or develops a rapidly worsening sore. This may indicate critically reduced circulation rather than a routine Raynaud’s attack.
In depth recent advances
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
Raynaud Disease treatment
Searching PubMed
systemic sclerosis Raynaud treatment
Searching the Web
2025 2026 Raynaud phenomenon management guideline EULAR systemic sclerosis digital ulcers PDE5 inhibitor bosentan
Reading Article
PMID: 38291895
Reading Article
PMID: 36066501
Reading Article
PMID: 39615000
Reading Article
PMID: 38956991
Reading Article
PMID: 33998674
Reading Web Page
https://ard.eular.org/article/S0003-4967(24)00584-3/fulltext
Reading File
Reading File
Recent advances in Raynaud’s finger management
Management has shifted from treating every patient with the same vasodilator to a risk-stratified approach:
- Confirm whether this is primary Raynaud’s or secondary disease.
- Identify people at risk of digital ischaemia, ulcers, or tissue loss.
- Escalate treatment according to severity and cause, particularly systemic sclerosis (scleroderma).
Most new evidence concerns systemic-sclerosis-associated Raynaud’s, which is more likely to cause fixed vessel damage, ulcers, infection, and fingertip tissue loss. Primary Raynaud’s is usually managed conservatively with medication only when attacks remain troublesome.
1. First advance: earlier differentiation of primary vs secondary Raynaud’s
The most important practical advance is not a new tablet. It is recognizing early when attacks represent underlying vascular or autoimmune disease.
Features favoring primary Raynaud’s
- Onset in teens or young adulthood
- Symmetric attacks
- No ulcers, tissue loss, or persistent ischaemia
- Normal nailfold capillaries
- Negative or low-risk autoimmune testing
- No systemic symptoms
Features needing rheumatology or vascular evaluation
- New onset after age 30, especially in men
- Severe, asymmetric, or one-finger involvement
- Pitting scars, ulcers, black tissue, or persistent colour change between attacks
- Puffy fingers, skin tightening, telangiectasia, reflux/difficulty swallowing, inflammatory joint symptoms, rashes, muscle weakness, or breathlessness
- Occupational vibration exposure or a culprit medication
- Abnormal antinuclear antibody testing or nailfold capillaroscopy
Nailfold capillaroscopy has become more central in this assessment. Enlarged capillaries, microhaemorrhages, capillary loss, and abnormal new vessel formation suggest a systemic-sclerosis spectrum disorder rather than uncomplicated primary Raynaud’s.
This matters because a person with a painful ulcer is no longer simply being treated for “cold fingers”. They may need urgent vasodilator therapy, wound care, infection assessment, and evaluation of the underlying disease.
2. Self-management remains first-line, but is more targeted
There is no replacement for prevention of cold-triggered vasospasm:
- Keep the entire body warm: head, trunk, feet, and hands.
- Use insulated gloves or mittens, hand warmers, and pre-warmed gloves before outdoor exposure.
- Avoid abrupt cold exposure, including cold food/freezer handling.
- Stop nicotine exposure, including smoking and vaping.
- Identify medication triggers. Examples include non-selective beta-blockers, sympathomimetic decongestants, ergot derivatives, some migraine drugs, stimulants, and certain chemotherapy drugs.
- Avoid vibrating tools where relevant.
- Use stress reduction and regular exercise as adjuncts.
The evidence for individual non-drug interventions is limited, but these measures are low risk and remain the base of all treatment plans. In systemic sclerosis, textbook guidance emphasizes warming, tobacco cessation, and avoiding stimulants before or alongside drug escalation. Rheumatology, 2-Volume Set, 2022, pp. 1506-1518.
A recent randomized trial found silver-fibre gloves were not clearly superior to standard gloves in systemic-sclerosis Raynaud’s, so ordinary well-insulated gloves are reasonable rather than investing in expensive specialist fabric products.
3. Calcium-channel blockers remain the main initial medicine
Long-acting dihydropyridine calcium-channel blockers are still the usual first prescription:
- Nifedipine, commonly modified-release
- Amlodipine as an alternative
They reduce attack frequency and severity by relaxing small arterial smooth muscle. The 2023 EULAR systemic-sclerosis recommendations, published in 2024, still give oral nifedipine first-line status for systemic-sclerosis-related Raynaud’s.
Side effects limit use in some people:
- Light-headedness or low blood pressure
- Headache and flushing
- Ankle swelling
- Palpitations
- Worsened reflux in susceptible people
Dose titration, rather than immediately using a high dose, is often what makes this approach tolerable. Rheumatology, 2-Volume Set, 2022, pp. 1518-1528.
What has changed?
The main change is that specialists now tend to move more readily to a second vasodilator when a calcium-channel blocker alone is inadequate, rather than persisting with poorly effective first-line treatment.
4. PDE-5 inhibitors are now established second-line therapy, especially in systemic sclerosis
Sildenafil and tadalafil are phosphodiesterase-5 inhibitors. They increase cyclic GMP signalling, promoting vasodilation.
They are increasingly used for:
- Persistent or severe Raynaud’s despite calcium-channel blockers
- Systemic-sclerosis-associated Raynaud’s
- Digital ulcers or threatened digital ischaemia, under specialist care
The updated EULAR guideline states that PDE-5 inhibitors should be considered for systemic-sclerosis-related Raynaud’s. The evidence synthesis cited by EULAR found improvements versus placebo in Raynaud Condition Score, daily attack frequency, and attack duration. See the EULAR systemic sclerosis recommendations.
Important safety point
PDE-5 inhibitors must not be combined with nitrates, including nitroglycerin products, because this can dangerously lower blood pressure. Headache, flushing, reflux, muscle aches, visual disturbance, and hypotension can occur.
Current expert guidance is therefore more “layered”:
- Calcium-channel blocker first
- Add or substitute PDE-5 inhibitor if severe, refractory, or secondary Raynaud’s
- Escalate rapidly for ulcers or critical ischaemia
The 2024 Portuguese evidence-based recommendations similarly place nifedipine first, with sildenafil, tadalafil, or intravenous iloprost as options for severe or refractory Raynaud’s and digital ulcers. Systematic review and guideline . Tier 1 . 2024, PMID: 38956991.
5. Intravenous iloprost for severe disease and threatened fingers
Intravenous iloprost, a prostacyclin analogue, is an important hospital or specialist-center treatment for:
- Severe refractory Raynaud’s
- Critical digital ischaemia
- Painful non-healing ulcers
- Systemic-sclerosis digital vasculopathy when oral treatment has failed
It is not a routine treatment for mild primary Raynaud’s. It requires monitoring because vasodilation can cause headache, flushing, jaw pain, nausea, and hypotension.
The EULAR recommendations retain intravenous iloprost for severe systemic-sclerosis Raynaud’s after oral therapy fails, and support it, with PDE-5 inhibitors, for systemic-sclerosis digital ulcers. EULAR guidance.
6. Digital ulcers: treatment and prevention are now considered separately
A key advance is recognising that a drug that helps prevent ulcers may not heal an existing ulcer.
For healing an active digital ulcer
Specialists consider:
- Optimising oral vasodilators
- PDE-5 inhibitor therapy
- Intravenous iloprost
- Analgesia
- Wound care and protection from trauma
- Swab/culture and antibiotics only when infection is suspected or confirmed
- Assessment for large-vessel obstruction, clot, embolic disease, or another cause of persistent one-finger ischaemia
For preventing recurrent systemic-sclerosis digital ulcers
Bosentan, an endothelin receptor antagonist, can reduce the number of new systemic-sclerosis digital ulcers. It does not reliably heal ulcers already present. It requires specialist prescribing and monitoring, including liver tests and pregnancy precautions.
EULAR recommends considering bosentan to reduce new digital ulcers in systemic sclerosis, while recommending PDE-5 inhibitors and/or IV iloprost for ulcer treatment. EULAR recommendations.
7. Botulinum toxin: promising in selected hands, not a standard cure
Injecting botulinum toxin around the digital neurovascular bundles has attracted interest because it may reduce sympathetic vasoconstriction and pain.
Current evidence
The evidence is mixed:
- A 2025 systematic review found signals for improved pain and hand function in scleroderma-associated Raynaud’s, but no significant overall improvement in Raynaud Condition Score. It concluded that the evidence is insufficient to establish botulinum toxin as first-line treatment. Systematic review . Tier 1 . 2025, PMID: 39615000.
- A multicentre, randomized, placebo-controlled phase III trial found no benefit for palmar botulinum toxin A injections in systemic-sclerosis Raynaud’s and reported more transient hand-muscle weakness. RCT . Tier 3 . 2023, PMID: 36066501.
Practical conclusion
Botulinum toxin may still be considered at an experienced specialist hand or vascular center for highly selected, refractory cases, especially with pain or threatened digits, but it is not a replacement for established vasodilator therapy and ulcer care.
8. Surgical approaches: more selective than before
Digital sympathectomy
Microsurgical interruption of sympathetic nerve fibres around affected digital arteries may be considered for:
- Severe refractory Raynaud’s
- Recurrent ulcers
- Threatened digit where medical treatment has failed
It can improve pain and ulcer healing in selected cases but recurrence occurs, and high-quality comparative evidence remains limited.
Revascularisation or other vascular intervention
If Raynaud-like symptoms are one-sided or involve only one or two fingers, clinicians should not assume primary Raynaud’s. Arterial imaging may reveal:
- Atherosclerotic or thrombotic obstruction
- Embolism
- Thoracic outlet-related arterial disease
- Hypothenar hammer syndrome
- Vasculitis
In these cases, treating the arterial lesion can be more important than escalating vasodilators.
9. Experimental and negative recent research: useful to know
Not every biologically plausible therapy works.
Vipoglanstat
Vipoglanstat inhibits microsomal prostaglandin E synthase-1, aiming to lower prostaglandin E2 and shift metabolism toward prostacyclin. In a 2025 phase II randomized trial of 69 people with systemic-sclerosis-related Raynaud’s, it achieved its biochemical effect and appeared well tolerated, but did not improve attacks, symptoms, or cold-challenge blood-flow recovery compared with placebo. Phase II RCT . Tier 3 . 2025, PMID: 38291895.
This illustrates a wider issue: advances in vascular biology have not yet produced a widely adopted new drug that displaces calcium-channel blockers, PDE-5 inhibitors, and prostacyclin therapy.
Emerging research directions
Current research is investigating:
- Better vascular imaging and biomarkers to predict ulcers
- Digital perfusion monitoring and thermal recovery testing
- Therapies targeting endothelial injury, impaired nitric oxide signalling, endothelin activity, and microvascular remodelling
- Better trial outcomes, since attack diaries and symptom scores are variable and placebo responses are substantial
- Local therapies, including refined botulinum injection techniques and regenerative approaches
These remain investigational rather than routine treatments.
Current practical escalation pathway
| Clinical situation | Typical approach |
|---|---|
| Mild, likely primary Raynaud’s | Warming, nicotine cessation, trigger reduction, reassurance |
| Bothersome primary Raynaud’s | Add or trial long-acting nifedipine or amlodipine |
| Persistent symptoms despite first-line drug | Review diagnosis and triggers; consider specialist-led alternative or PDE-5 inhibitor |
| Systemic sclerosis or another connective-tissue disease | Early rheumatology input; calcium-channel blocker, then consider PDE-5 inhibitor |
| Digital ulcer | Urgent specialist assessment; wound care, analgesia, assess infection and circulation; PDE-5 inhibitor and/or IV iloprost as appropriate |
| Recurrent systemic-sclerosis ulcers | Consider preventive bosentan under specialist monitoring |
| Threatened finger, persistent blue/black finger, severe rest pain | Same-day emergency vascular/rheumatology assessment, not home management |
When urgent assessment is needed
Seek urgent medical assessment for:
- A finger that remains pale, blue, purple, or black after warming
- Severe pain at rest, loss of sensation, or a persistently cold digit
- New ulcer, discharge, spreading redness, fever, or suspected infection
- Rapidly worsening fingertip wound
- One-finger or one-hand ischaemia, particularly if new
These signs may reflect critical ischaemia, thrombosis, embolic disease, infection, or severe secondary Raynaud’s rather than a routine attack.
Bottom line: the meaningful recent change is earlier recognition of secondary Raynaud’s and faster escalation for vascular complications. Calcium-channel blockers remain the starting drug; PDE-5 inhibitors and IV iloprost are now firmly embedded for severe systemic-sclerosis-related disease; bosentan is for preventing recurrent systemic-sclerosis ulcers; and botulinum toxin remains an uncertain, specialist-only option rather than established standard care.
This is a shared conversation. Sign in to Orris to start your own chat.